Trial Profile

Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis - ZODIPSO Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tildrakizumab (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms ZODIPSO

Most Recent Events

24 Sep 2025 Planned End Date changed from 1 Apr 2025 to 15 Oct 2025.
24 Sep 2025 Status changed from recruiting to active, no longer recruiting.
17 Sep 2025 According to an Almirall, S.A. media release, data from this study will be presented at the 34th European Academy of Dermatology and Venereology Congress (EADV) taking place from September 17 to 20 in Paris, France.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com